InMed Pharmaceuticals Inc. (INM)
USD 1.87
(1.62%)
USD 1.87
(1.62%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 9.01 Billion USD | 92068.33% |
| 2023 | 9.78 Million USD | -31.76% |
| 2022 | 14.33 Million USD | 44.24% |
| 2021 | 9.93 Million USD | 12.07% |
| 2020 | 8.86 Million CAD | -14.67% |
| 2019 | 10.39 Million CAD | 55.46% |
| 2018 | 6.68 Million USD | 94.36% |
| 2017 | 3.43 Million CAD | 87.21% |
| 2016 | 1.83 Million CAD | -46.84% |
| 2015 | 3.45 Million CAD | 200.21% |
| 2014 | 1.15 Million CAD | 2362.88% |
| 2013 | 46.74 Thousand CAD | -72.27% |
| 2012 | 168.6 Thousand CAD | -60.53% |
| 2011 | 427.21 Thousand CAD | -11.39% |
| 2010 | 482.1 Thousand CAD | -42.37% |
| 2009 | 836.53 Thousand CAD | -43.78% |
| 2008 | 1.48 Million CAD | -12.17% |
| 2007 | 1.69 Million CAD | -32.72% |
| 2006 | 2.51 Million CAD | -16.92% |
| 2005 | 3.03 Million CAD | 41.96% |
| 2004 | 2.13 Million CAD | 55.11% |
| 2003 | 1.37 Million CAD | -49.93% |
| 2002 | 2.74 Million CAD | -35.14% |
| 2001 | 4.23 Million CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 1.93 Million USD | -4.62% |
| 2024 Q4 | 9 Billion USD | -75.92% |
| 2024 Q1 | 2.59 Million USD | 24.16% |
| 2024 Q2 | 2.02 Million USD | -21.69% |
| 2023 Q1 | 2.98 Million USD | -5.21% |
| 2023 Q2 | 2.36 Million USD | -20.85% |
| 2023 Q4 | 2.08 Million USD | -10.89% |
| 2023 Q3 | 2.34 Million USD | -1.0% |
| 2023 FY | 9.78 Million USD | -31.76% |
| 2022 Q1 | 2.89 Million USD | -12.51% |
| 2022 Q4 | 3.15 Million USD | -11.92% |
| 2022 FY | 14.33 Million USD | 44.24% |
| 2022 Q3 | 3.57 Million USD | -19.09% |
| 2022 Q2 | 4.42 Million USD | 52.93% |
| 2021 Q1 | 1.56 Million CAD | -17.06% |
| 2021 FY | 9.93 Million USD | 12.07% |
| 2021 Q3 | 3.13 Million USD | 62.01% |
| 2021 Q4 | 3.3 Million USD | 5.51% |
| 2021 Q2 | 1.93 Million USD | 23.68% |
| 2020 Q1 | 3.01 Million CAD | -11.31% |
| 2020 FY | 8.86 Million CAD | -14.67% |
| 2020 Q3 | 2.15 Million CAD | -16.61% |
| 2020 Q2 | 2.57 Million CAD | -14.35% |
| 2020 Q4 | 1.88 Million CAD | -12.31% |
| 2019 Q2 | 2.14 Million CAD | -4.21% |
| 2019 Q4 | 3.39 Million CAD | 28.51% |
| 2019 Q1 | 2.24 Million CAD | -1.35% |
| 2019 FY | 10.39 Million CAD | 55.46% |
| 2019 Q3 | 2.64 Million CAD | 23.05% |
| 2018 Q1 | 1.46 Million CAD | -1.77% |
| 2018 FY | 6.68 Million USD | 94.36% |
| 2018 Q4 | 2.27 Million CAD | 35.91% |
| 2018 Q3 | 1.67 Million CAD | 35.86% |
| 2018 Q2 | 1.23 Million CAD | -15.95% |
| 2017 Q4 | 1.49 Million CAD | 60.32% |
| 2017 Q3 | 929.39 Thousand CAD | 32.88% |
| 2017 Q2 | 699.43 Thousand CAD | 118.69% |
| 2017 Q1 | 319.82 Thousand CAD | -19.25% |
| 2017 FY | 3.43 Million CAD | 87.21% |
| 2016 Q4 | 396.09 Thousand CAD | 35.0% |
| 2016 Q2 | 558.33 Thousand CAD | 8.09% |
| 2016 Q1 | 516.54 Thousand CAD | -57.47% |
| 2016 FY | 1.83 Million CAD | -46.84% |
| 2016 Q3 | 293.39 Thousand CAD | -47.45% |
| 2015 Q1 | 584.48 Thousand CAD | -42.41% |
| 2015 Q2 | 489.7 Thousand CAD | -16.22% |
| 2015 Q4 | 1.21 Million CAD | -5.02% |
| 2015 FY | 3.45 Million CAD | 200.21% |
| 2015 Q3 | 1.27 Million CAD | 161.14% |
| 2014 FY | 1.15 Million CAD | 2362.88% |
| 2014 Q3 | 92.31 Thousand CAD | 162.09% |
| 2014 Q4 | 1.01 Million CAD | 999.31% |
| 2014 Q1 | 10.98 Thousand CAD | -51.74% |
| 2014 Q2 | 35.22 Thousand CAD | 220.68% |
| 2013 Q4 | 22.76 Thousand CAD | 198.67% |
| 2013 FY | 46.74 Thousand CAD | -72.27% |
| 2013 Q1 | 22.94 Thousand CAD | -70.25% |
| 2013 Q3 | 7621.01 CAD | 227.81% |
| 2013 Q2 | -5962.83 CAD | -125.99% |
| 2012 Q4 | 77.12 Thousand CAD | 240.46% |
| 2012 Q3 | 22.65 Thousand CAD | -13.71% |
| 2012 Q2 | 26.25 Thousand CAD | -34.93% |
| 2012 Q1 | 40.34 Thousand CAD | -49.79% |
| 2012 FY | 168.6 Thousand CAD | -60.53% |
| 2011 FY | 427.21 Thousand CAD | -11.39% |
| 2011 Q3 | 240.34 Thousand CAD | 443.03% |
| 2011 Q4 | 80.34 Thousand CAD | -66.57% |
| 2011 Q2 | 44.26 Thousand CAD | -22.95% |
| 2011 Q1 | 57.44 Thousand CAD | -71.62% |
| 2010 Q3 | 91.25 Thousand CAD | 3.97% |
| 2010 Q4 | 202.39 Thousand CAD | 121.79% |
| 2010 Q1 | 93.75 Thousand CAD | -19.8% |
| 2010 Q2 | 87.77 Thousand CAD | -6.38% |
| 2010 FY | 482.1 Thousand CAD | -42.37% |
| 2009 Q1 | 438.03 Thousand CAD | -32.1% |
| 2009 Q3 | 99.25 Thousand CAD | -61.34% |
| 2009 Q2 | 256.76 Thousand CAD | -41.38% |
| 2009 Q4 | 116.9 Thousand CAD | 17.79% |
| 2009 FY | 836.53 Thousand CAD | -43.78% |
| 2008 Q1 | 308.03 Thousand CAD | 103.88% |
| 2008 Q4 | 645.1 Thousand CAD | 132.23% |
| 2008 Q3 | 277.78 Thousand CAD | -48.11% |
| 2008 Q2 | 535.37 Thousand CAD | 73.8% |
| 2008 FY | 1.48 Million CAD | -12.17% |
| 2007 Q2 | 290.92 Thousand CAD | -20.62% |
| 2007 Q4 | -7.93 Million CAD | -2916.83% |
| 2007 Q1 | 366.47 Thousand CAD | -9.5% |
| 2007 Q3 | 281.84 Thousand CAD | -3.12% |
| 2007 FY | 1.69 Million CAD | -32.72% |
| 2006 Q1 | 651.01 Thousand CAD | -11.99% |
| 2006 Q3 | 663.66 Thousand CAD | -10.05% |
| 2006 Q2 | 737.82 Thousand CAD | 13.33% |
| 2006 Q4 | 404.96 Thousand CAD | -38.98% |
| 2006 FY | 2.51 Million CAD | -16.92% |
| 2005 FY | 3.03 Million CAD | 41.96% |
| 2005 Q4 | 739.69 Thousand CAD | 15.34% |
| 2005 Q3 | 641.29 Thousand CAD | -12.35% |
| 2005 Q2 | 731.63 Thousand CAD | -17.33% |
| 2005 Q1 | 884.96 Thousand CAD | -0.01% |
| 2004 Q1 | 456.44 Thousand CAD | -8.98% |
| 2004 FY | 2.13 Million CAD | 55.11% |
| 2004 Q4 | 885.04 Thousand CAD | 136.04% |
| 2004 Q3 | 374.94 Thousand CAD | -19.38% |
| 2004 Q2 | 465.06 Thousand CAD | 1.89% |
| 2003 Q1 | 322.71 Thousand CAD | -42.92% |
| 2003 FY | 1.37 Million CAD | -49.93% |
| 2003 Q4 | 501.47 Thousand CAD | 114.05% |
| 2003 Q2 | 272.78 Thousand CAD | -15.47% |
| 2003 Q3 | 234.27 Thousand CAD | -14.12% |
| 2002 Q1 | 752.56 Thousand CAD | 0.0% |
| 2002 Q2 | 729.71 Thousand CAD | -3.04% |
| 2002 FY | 2.74 Million CAD | -35.14% |
| 2002 Q4 | 565.39 Thousand CAD | -17.37% |
| 2002 Q3 | 684.23 Thousand CAD | -6.23% |
| 2001 FY | 4.23 Million CAD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AbCellera Biologics Inc. | 275.23 Million USD | -3175.689% |
| Alkermes plc | 996.24 Million USD | -804.972% |
| Agenus Inc. | 78.18 Million USD | -11431.59% |
| Aptorum Group Limited | 10.56 Thousand USD | -85327772.421% |
| Ardelyx, Inc. | 169.93 Million USD | -5205.344% |
| Dyadic International, Inc. | 9.15 Million USD | -98403.687% |
| Eton Pharmaceuticals, Inc. | 22.25 Million USD | -40414.731% |
| Lantern Pharma Inc. | 17.87 Million USD | -50330.472% |
| Inhibikase Therapeutics, Inc. | 6.73 Million USD | -133824.807% |
| Novavax, Inc. | 779.12 Million USD | -1057.163% |
| Janux Therapeutics, Inc. | 81.06 Million USD | -11022.034% |
| Pyxis Oncology, Inc. | 82.19 Million USD | -10868.591% |
| TransCode Therapeutics, Inc. | 19.41 Million USD | -46328.589% |
| Ocuphire Pharma, Inc. | 29.6 Million USD | -30352.418% |
| Outlook Therapeutics, Inc. | 53.12 Million USD | -16870.369% |
| Madrigal Pharmaceuticals, Inc. | 380.49 Million USD | -2269.471% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -36991.737% |
| SELLAS Life Sciences Group, Inc. | 37.86 Million USD | -23707.713% |
| Syros Pharmaceuticals, Inc. | 30.77 Million USD | -29199.48% |
| Barinthus Biotherapeutics plc | 84.71 Million USD | -10542.314% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -51545.432% |
| Xeris Biopharma Holdings, Inc. | 168.43 Million USD | -5252.622% |
| Clearside Biomedical, Inc. | 32.71 Million USD | -27458.438% |
| C4 Therapeutics, Inc. | 159.78 Million USD | -5542.351% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | -400.858% |
| AlloVir, Inc. | 180.93 Million USD | -4882.918% |
| Arrowhead Pharmaceuticals, Inc. | 445.73 Million USD | -1922.66% |
| VYNE Therapeutics Inc. | 29.68 Million USD | -30274.446% |
| Bicycle Therapeutics plc | 216.92 Million USD | -4056.214% |
| BioXcel Therapeutics, Inc. | 171.9 Million USD | -5144.699% |
| ChromaDex Corporation | 56.37 Million USD | -15891.314% |
| Chimerix, Inc. | 93.38 Million USD | -9553.967% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -64716.504% |
| Caribou Biosciences, Inc. | 150.53 Million USD | -5889.094% |
| CRISPR Therapeutics AG | 463.49 Million USD | -1845.169% |
| Precision BioSciences, Inc. | 92.46 Million USD | -9650.649% |
| Fate Therapeutics, Inc. | 254.04 Million USD | -3448.89% |
| Fortress Biotech, Inc. | 200.19 Million USD | -4403.481% |
| Fortress Biotech, Inc. | 200.19 Million USD | -4403.481% |
| HOOKIPA Pharma Inc. | 32.74 Million USD | -27432.349% |
| ImmuCell Corporation | 9.61 Million USD | -93644.449% |
| IDEAYA Biosciences, Inc. | 157.81 Million USD | -5612.892% |
| Immix Biopharma, Inc. | 16.14 Million USD | -55755.77% |
| Incyte Corporation | 1.19 Billion USD | -657.31% |
| Innoviva, Inc. | 132.15 Million USD | -6722.149% |
| IO Biotech, Inc. | 91.44 Million USD | -9759.413% |
| Jaguar Health, Inc. | 42.01 Million USD | -21358.391% |
| Keros Therapeutics, Inc. | 169.27 Million USD | -5226.03% |
| Ligand Pharmaceuticals Incorporated | 84.32 Million USD | -10591.914% |
| ContextLogic Inc. | 387 Million USD | -2229.649% |
| MiMedx Group, Inc. | 229.72 Million USD | -3824.547% |
| MEI Pharma, Inc. | 34.78 Million USD | -25818.479% |
| NextCure, Inc. | 67.63 Million USD | -13229.602% |
| Onconetix, Inc. | 34.9 Million USD | -25727.576% |
| Oncternal Therapeutics, Inc. | 12.74 Million USD | -70633.901% |
| Opthea Limited | 191.96 Million USD | -4596.497% |
| Psyence Biomedical Ltd. | 2.75 Million USD | -327556.351% |
| Vaxcyte, Inc. | 468.04 Million USD | -1826.272% |
| PDS Biotechnology Corporation | 43.04 Million USD | -20844.811% |
| Precigen, Inc. | 84.18 Million USD | -10609.95% |
| Pharming Group N.V. | 225.49 Million USD | -3898.272% |
| Phathom Pharmaceuticals, Inc. | 167.82 Million USD | -5272.046% |
| Pieris Pharmaceuticals, Inc. | 72.56 Million USD | -12324.197% |
| PureTech Health plc | 144.59 Million USD | -6135.083% |
| Rigel Pharmaceuticals, Inc. | 130.26 Million USD | -6821.185% |
| Avidity Biosciences, Inc. | 245.15 Million USD | -3577.523% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -36991.737% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | -3842.515% |
| Sol-Gel Technologies Ltd. | 30.85 Million USD | -29115.927% |
| Acelyrin, Inc. | 422.06 Million USD | -2036.108% |
| Salarius Pharmaceuticals, Inc. | 12.89 Thousand USD | -69921902.482% |
| Summit Therapeutics Inc. | 87.68 Million USD | -10181.85% |
| Sensei Biotherapeutics, Inc. | 37.06 Million USD | -24224.798% |
| Senti Biosciences, Inc. | 94.7 Million USD | -9419.817% |
| Stoke Therapeutics, Inc. | 123.55 Million USD | -7197.065% |
| Elevation Oncology, Inc. | 45.44 Million USD | -19738.801% |
| Alaunos Therapeutics, Inc. | 29.46 Million USD | -30493.99% |
| Telomir Pharmaceuticals, Inc. Common Stock | 3.94 Million USD | -228607.083% |
| Entrada Therapeutics, Inc. | 132.17 Million USD | -6721.065% |
| VistaGen Therapeutics, Inc. | 34.08 Million USD | -26350.764% |
| Kintara Therapeutics, Inc. | 8.45 Million USD | -106582.558% |
| Wave Life Sciences Ltd. | 181.3 Million USD | -4872.804% |
| Seer, Inc. | 110.49 Million USD | -8059.782% |
| Verrica Pharmaceuticals Inc. | 70.59 Million USD | -12671.26% |
| Aadi Bioscience, Inc. | 93.47 Million USD | -9544.775% |
| ESSA Pharma Inc. | 32.13 Million USD | -27956.619% |
| GlycoMimetics, Inc. | 39.28 Million USD | -22849.41% |
| GT Biopharma, Inc. | 13.57 Million USD | -66309.421% |
| Inhibrx Biosciences, Inc. | 219.83 Million USD | -4001.234% |
| Akebia Therapeutics, Inc. | 201.11 Million USD | -4382.879% |
| Catalyst Pharmaceuticals, Inc. | 259.42 Million USD | -3375.279% |
| Longboard Pharmaceuticals, Inc. | 56.75 Million USD | -15784.253% |
| Orchestra BioMed Holdings, Inc. | 54.08 Million USD | -16571.122% |
| Alzamend Neuro, Inc. | 9.93 Million USD | -90623.134% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | -2134.036% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | -47529.262% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | -17684.986% |
| Rocket Pharmaceuticals, Inc. | 259.65 Million USD | -3372.147% |
| Aptose Biosciences Inc. | 52.35 Million USD | -17120.076% |
| ZyVersa Therapeutics, Inc. | 14.41 Million USD | -62464.254% |
| Soligenix, Inc. | 7.79 Million USD | -115556.866% |
| Century Therapeutics, Inc. | 56.07 Million USD | -15979.155% |
| Kura Oncology, Inc. | 165.8 Million USD | -5337.591% |
| TScan Therapeutics, Inc. | 114.5 Million USD | -7773.53% |
| Intensity Therapeutics, Inc. | 8.31 Million USD | -108275.322% |
| Ocean Biomedical, Inc. | 2.48 Million USD | -363197.925% |
| CytomX Therapeutics, Inc. | 107.69 Million USD | -8271.319% |
| Autolus Therapeutics plc | 196.72 Million USD | -4482.893% |
| Mineralys Therapeutics, Inc. | 84.65 Million USD | -10549.731% |
| EyePoint Pharmaceuticals, Inc. | 116.45 Million USD | -7641.959% |
| Eterna Therapeutics Inc. | 19.38 Million USD | -46413.661% |
| Adaptive Biotechnologies Corporation | 321.75 Million USD | -2702.026% |
| GRI Bio, Inc. | 11.33 Million USD | -79474.078% |
| Xenetic Biosciences, Inc. | 7.05 Million USD | -127679.55% |
| Tenaya Therapeutics, Inc. | 131.19 Million USD | -6772.122% |
| IGM Biosciences, Inc. | 265.59 Million USD | -3294.597% |
| INmune Bio, Inc. | 29.89 Million USD | -30057.021% |
| Heron Therapeutics, Inc. | 172.55 Million USD | -5124.882% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -22263.629% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -56321.174% |
| Entero Therapeutics, Inc. | 15.74 Million USD | -57173.529% |
| Milestone Pharmaceuticals Inc. | 62.09 Million USD | -14418.572% |
| X4 Pharmaceuticals, Inc. | 107.52 Million USD | -8285.022% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | -3170.211% |
| Coherus BioSciences, Inc. | 301.45 Million USD | -2890.782% |
| Verastem, Inc. | 92.08 Million USD | -9690.781% |
| Abeona Therapeutics Inc. | 17.93 Million USD | -50157.776% |
| Pliant Therapeutics, Inc. | 185.72 Million USD | -4754.351% |
| Tonix Pharmaceuticals Holding Corp. | 121.4 Million USD | -7326.049% |
| Histogen Inc. | 14.27 Million USD | -63070.845% |
| Aprea Therapeutics, Inc. | 16.04 Million USD | -56079.357% |
| Surrozen, Inc. | 18.55 Million USD | -48502.388% |
| Organovo Holdings, Inc. | 14.91 Million USD | -60347.489% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -177018.369% |
| Ovid Therapeutics Inc. | 59.67 Million USD | -15008.54% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | -35053.207% |
| CASI Pharmaceuticals, Inc. | 47 Million USD | -19079.983% |
| Cadrenal Therapeutics, Inc. Common Stock | 7.63 Million USD | -118017.758% |
| Centessa Pharmaceuticals plc | 178.13 Million USD | -4961.157% |
| Hepion Pharmaceuticals, Inc. | 48.44 Million USD | -18509.131% |
| Arcturus Therapeutics Holdings Inc. | 245 Million USD | -3579.835% |
| BioRestorative Therapies, Inc. | 15.36 Million USD | -58571.133% |
| Apollomics, Inc. | 54.14 Million USD | -16552.647% |
| Amarin Corporation plc | 272.35 Million USD | -3210.267% |
| Mesoblast Limited | 5.9 Million USD | -152657.421% |
| Turnstone Biologics Corp. | 78.33 Million USD | -11408.774% |
| Kymera Therapeutics, Inc. | 244.12 Million USD | -3593.13% |
| Synaptogenix, Inc. | 8.31 Million USD | -108342.402% |
| Tiziana Life Sciences Ltd | 14.58 Million USD | -61710.935% |
| Aurinia Pharmaceuticals Inc. | 253.05 Million USD | -3462.746% |
| BriaCell Therapeutics Corp. | 33.33 Million USD | -26949.872% |
| Monopar Therapeutics Inc. | 8.83 Million USD | -101989.266% |
| Exelixis, Inc. | 1.58 Billion USD | -468.18% |
| Better Therapeutics, Inc. | 38.26 Million USD | -23463.178% |
| Nurix Therapeutics, Inc. | 232.05 Million USD | -3785.259% |
| Apellis Pharmaceuticals, Inc. | 855.2 Million USD | -954.224% |
| NLS Pharmaceutics AG | 11.8 Million USD | -76258.896% |
| Dermata Therapeutics, Inc. | 8.04 Million USD | -112009.53% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | -29959.491% |
| Gritstone bio, Inc. | 148.37 Million USD | -5976.363% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -12992.669% |
| TNF Pharmaceuticals, Inc. | 16.36 Million USD | -55007.719% |
| Avid Bioservices, Inc. | 25.99 Million USD | -34581.27% |
| Insmed Incorporated | 949.26 Million USD | -849.764% |
| Virpax Pharmaceuticals, Inc. | 15.68 Million USD | -57362.491% |
| MediWound Ltd. | 18.86 Million USD | -47683.247% |
| OmniAb, Inc. | 83.89 Million USD | -10646.46% |
| Alector, Inc. | 248.8 Million USD | -3523.662% |
| Seres Therapeutics, Inc. | 234.3 Million USD | -3747.817% |
| Checkpoint Therapeutics, Inc. | 52.25 Million USD | -17154.68% |
| Zai Lab Limited | 547.47 Million USD | -1546.783% |
| Revance Therapeutics, Inc. | 398.65 Million USD | -2161.546% |
| Aura Biosciences, Inc. | 84.99 Million USD | -10507.88% |
| Lyell Immunopharma, Inc. | 247.13 Million USD | -3548.06% |
| Immunic, Inc. | 99.22 Million USD | -8986.344% |
| Tarsus Pharmaceuticals, Inc. | 159.01 Million USD | -5569.851% |
| Veracyte, Inc. | 357.93 Million USD | -2418.835% |
| FibroGen, Inc. | 398.11 Million USD | -2164.619% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -63346.467% |
| Adial Pharmaceuticals, Inc. | 6.88 Million USD | -130791.585% |
| Sonnet BioTherapeutics Holdings, Inc. | 7.12 Million USD | -126423.745% |
| Jazz Pharmaceuticals plc | 3.25 Billion USD | -176.928% |
| Cyclacel Pharmaceuticals, Inc. | 25.87 Million USD | -34746.145% |
| Amylyx Pharmaceuticals, Inc. | 316.54 Million USD | -2748.189% |
| TG Therapeutics, Inc. | 198.47 Million USD | -4442.508% |
| Galecto, Inc. | 35.62 Million USD | -25205.928% |
| Calithera Biosciences, Inc. | 40.68 Million USD | -22057.691% |
| Fortrea Holdings Inc. | 457.3 Million USD | -1871.516% |
| KalVista Pharmaceuticals, Inc. | 54.27 Million USD | -16510.308% |
| Aptevo Therapeutics Inc. | 28.87 Million USD | -31120.109% |
| XBiotech Inc. | 37.51 Million USD | -23935.572% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -12992.669% |
| Lyra Therapeutics, Inc. | 20.64 Million USD | -43561.887% |
| Foghorn Therapeutics Inc. | 142.06 Million USD | -6246.389% |
| Y-mAbs Therapeutics, Inc. | 99.07 Million USD | -8999.917% |
| Theravance Biopharma, Inc. | 110.71 Million USD | -8043.126% |
| Ultragenyx Pharmaceutical Inc. | 958.24 Million USD | -840.857% |
| Metagenomi, Inc. Common Stock | 28.84 Million USD | -31155.826% |
| Vaxxinity, Inc. | 56.05 Million USD | -15984.892% |
| BioCryst Pharmaceuticals, Inc. | 430.64 Million USD | -1993.568% |
| Gain Therapeutics, Inc. | 22.3 Million USD | -40314.275% |
| Cartesian Therapeutics, Inc. | 110.86 Million USD | -8032.035% |
| NexImmune, Inc. | 28.16 Million USD | -31907.597% |
| Creative Medical Technology Holdings, Inc. | 5.53 Million USD | -162905.384% |
| Marker Therapeutics, Inc. | 17.89 Million USD | -50288.361% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | -220.241% |
| Chemomab Therapeutics Ltd. | 25.45 Million USD | -35312.793% |
| Scopus BioPharma Inc. | 11.71 Million USD | -76859.775% |
| RAPT Therapeutics, Inc. | 127.06 Million USD | -6995.546% |
| Ainos, Inc. | 12.95 Million USD | -69505.324% |
| Pluri Inc. | 22.48 Million USD | -40005.618% |
| Prothena Corporation plc | 282.4 Million USD | -3092.476% |
| Adaptimmune Therapeutics plc | 200.02 Million USD | -4407.376% |
| Celularity Inc. | 215.05 Million USD | -4092.238% |
| Rallybio Corporation | 78.93 Million USD | -11322.165% |
| Cue Biopharma, Inc. | 19.54 Million USD | -46035.211% |
| MeiraGTx Holdings plc | 151.07 Million USD | -5867.608% |
| Omeros Corporation | 94.75 Million USD | -9415.196% |
| Humacyte, Inc. | 23.49 Million USD | -38269.762% |
| Immunocore Holdings plc | 308.04 Million USD | -2826.809% |
| Cocrystal Pharma, Inc. | 3.39 Million USD | -265851.121% |
| Cidara Therapeutics, Inc. | 86.86 Million USD | -10279.028% |
| Blueprint Medicines Corporation | 722.86 Million USD | -1147.231% |
| CalciMedica, Inc. | 21.81 Million USD | -41224.394% |
| Cabaletta Bio, Inc. | 74.66 Million USD | -11975.734% |
| Marinus Pharmaceuticals, Inc. | 160.54 Million USD | -5515.886% |
| Scholar Rock Holding Corporation | 171.29 Million USD | -5163.284% |
| Sana Biotechnology, Inc. | 294.94 Million USD | -2956.806% |
| Pulmatrix, Inc. | 22.03 Million USD | -40809.987% |
| Elicio Therapeutics, Inc. | 34.57 Million USD | -25975.902% |
| Vigil Neuroscience, Inc. | 88.86 Million USD | -10045.323% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | -1534.572% |
| Adlai Nortye Ltd. American Depositary Shares | 72.55 Million USD | -12326.766% |
| Cytokinetics, Incorporated | 173.61 Million USD | -5093.041% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | -26094.088% |
| Nutriband Inc. | 5.73 Million USD | -157132.198% |
| Protara Therapeutics, Inc. | 43.61 Million USD | -20572.146% |
| Vor Biopharma Inc. | 126.03 Million USD | -7053.308% |
| Roivant Sciences Ltd. | 1.18 Billion USD | -658.149% |
| Evogene Ltd. | 27.79 Million USD | -32342.4% |
| ProKidney Corp. | 151.52 Million USD | -5850.121% |
| Applied Therapeutics, Inc. | 74.17 Million USD | -12054.692% |
| Hoth Therapeutics, Inc. | 7.69 Million USD | -117105.66% |
| BridgeBio Pharma, Inc. | 614.22 Million USD | -1367.819% |
| CorMedix Inc. | 48.95 Million USD | -18315.34% |
| BioLineRx Ltd. | 50.8 Million USD | -17646.827% |
| Tango Therapeutics, Inc. | 150.7 Million USD | -5882.577% |
| Galectin Therapeutics Inc. | 38.07 Million USD | -23580.771% |
| Atai Life Sciences N.V. | 125.78 Million USD | -7067.582% |
| Renovaro Biosciences Inc. | 81.63 Million USD | -10943.387% |
| Aerovate Therapeutics, Inc. | 81.4 Million USD | -10974.627% |
| Zentalis Pharmaceuticals, Inc. | 252.55 Million USD | -3469.856% |
| Sagimet Biosciences Inc. | 32.74 Million USD | -27437.395% |
| MediciNova, Inc. | 10.9 Million USD | -82611.228% |
| Praxis Precision Medicines, Inc. | 128.82 Million USD | -6898.714% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -124091.93% |
| GeoVax Labs, Inc. | 6.02 Million USD | -149609.133% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | -1792.632% |
| Biomea Fusion, Inc. | 126.13 Million USD | -7047.693% |
| PTC Therapeutics, Inc. | 1.31 Billion USD | -587.26% |
| Mereo BioPharma Group plc | 35.84 Million USD | -25054.129% |
| Cullinan Oncology, Inc. | 191.08 Million USD | -4618.086% |
| Syndax Pharmaceuticals, Inc. | 229.95 Million USD | -3820.672% |
| Absci Corporation | 73.66 Million USD | -12138.676% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -32587.053% |
| 4D Molecular Therapeutics, Inc. | 133.59 Million USD | -6648.816% |
| Dyne Therapeutics, Inc. | 242.16 Million USD | -3623.021% |
| Kiniksa Pharmaceuticals, Ltd. | 262.04 Million USD | -3340.493% |
| Ventyx Biosciences, Inc. | 207.99 Million USD | -4234.617% |
| Allakos Inc. | 196.05 Million USD | -4498.555% |
| Imunon, Inc. | 20.31 Million USD | -44289.731% |
| Fulcrum Therapeutics, Inc. | 113.46 Million USD | -7845.556% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | -2345.863% |
| BioAtla, Inc. | 129.68 Million USD | -6851.925% |
| NLS Pharmaceutics AG | 11.8 Million USD | -76258.896% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | -56806.792% |
| Allogene Therapeutics, Inc. | 84.91 Million USD | -10516.999% |
| Larimar Therapeutics, Inc. | 41.75 Million USD | -21490.457% |
| XOMA Corporation | 46.46 Million USD | -19304.134% |
| Kezar Life Sciences, Inc. | 111.17 Million USD | -8009.798% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -6228.48% |
| aTyr Pharma, Inc. | 12.97 Million USD | -69364.08% |
| Aligos Therapeutics, Inc. | 103.65 Million USD | -8597.753% |
| Akero Therapeutics, Inc. | 172.87 Million USD | -5115.331% |
| Viridian Therapeutics, Inc. | 254.76 Million USD | -3438.861% |
| Eliem Therapeutics, Inc. | 37.4 Million USD | -24001.109% |
| EyeGate Pharmaceuticals, Inc. | 8.22 Million USD | -109516.376% |
| Akari Therapeutics, Plc | 16.8 Million USD | -53545.978% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -396375.899% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | -2912.095% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -133888.776% |
| UroGen Pharma Ltd. | 138.88 Million USD | -6391.377% |
| Sutro Biopharma, Inc. | 243 Million USD | -3610.045% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | -123834.178% |
| Orgenesis Inc. | 45.75 Million USD | -19603.527% |
| Entera Bio Ltd. | 8.86 Million USD | -101657.822% |
| GH Research PLC | 41.22 Million USD | -21771.193% |
| Lisata Therapeutics, Inc. | 25.7 Million USD | -34969.795% |
| Reneo Pharmaceuticals, Inc. | 83.05 Million USD | -10755.409% |
| Xencor, Inc. | 306.97 Million USD | -2836.944% |
| 60 Degrees Pharmaceuticals, Inc. | 4.93 Million USD | -182641.447% |
| Replimune Group, Inc. | 234.77 Million USD | -3740.196% |
| Coeptis Therapeutics Holdings, Inc. | 20.48 Million USD | -43900.938% |
| Vanda Pharmaceuticals Inc. | 191.79 Million USD | -4600.694% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -133888.776% |
| Portage Biotech Inc. | 18.19 Million USD | -49439.771% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -124091.93% |
| Olema Pharmaceuticals, Inc. | 104.96 Million USD | -8489.612% |
| OncoCyte Corporation | 25.63 Million USD | -35066.919% |
| Qualigen Therapeutics, Inc. | 6.09 Million USD | -147805.582% |
| Processa Pharmaceuticals, Inc. | 11.45 Million USD | -78591.586% |
| Purple Biotech Ltd. | -22.46 Million USD | 40228.824% |
| CollPlant Biotechnologies Ltd. | 16.48 Million USD | -54607.178% |
| scPharmaceuticals Inc. | 65.17 Million USD | -13732.494% |
| ProMIS Neurosciences, Inc. | 8.45 Million USD | -106560.648% |
| HilleVax, Inc. | 133.34 Million USD | -6661.216% |
| NeuroSense Therapeutics Ltd. | 10.28 Million USD | -87559.144% |
| Tharimmune, Inc. | 9.45 Million USD | -95252.017% |
| Genprex, Inc. | 31.06 Million USD | -28926.332% |
| Neumora Therapeutics, Inc. Common Stock | 187.52 Million USD | -4707.73% |
| Atossa Therapeutics, Inc. | 31.37 Million USD | -28633.604% |
| XTL Biopharmaceuticals Ltd. | 765 Thousand USD | -1178428.497% |
| Virios Therapeutics, Inc. | 5.44 Million USD | -165420.049% |
| OKYO Pharma Limited | 8243.57 USD | -109366873.289% |
| Savara Inc. | 15.74 Million USD | -57160.991% |
| Curis, Inc. | 58.35 Million USD | -15349.821% |
| Daré Bioscience, Inc. | 33.6 Million USD | -26725.062% |
| Carmell Therapeutics Corporation | 5.09 Million USD | -176940.044% |
| Titan Pharmaceuticals, Inc. | 7.46 Million USD | -120738.266% |
| Achieve Life Sciences, Inc. | 27.02 Million USD | -33264.455% |
| BeiGene, Ltd. | 3.28 Billion USD | -174.319% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | -45115.945% |
| Revolution Medicines, Inc. Warrant | 498.76 Million USD | -1707.613% |
| Protagonist Therapeutics, Inc. | 153.65 Million USD | -5767.638% |
| Erasca, Inc. | 141.52 Million USD | -6270.424% |
| bluebird bio, Inc. | 240.23 Million USD | -3652.932% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -199056.059% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | -416.284% |
| DBV Technologies S.A. | 92.16 Million USD | -9682.707% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -199056.059% |
| Moderna, Inc. | 6.39 Billion USD | -41.003% |
| Vincerx Pharma, Inc. | 42.6 Million USD | -21059.246% |
| Fresh Tracks Therapeutics, Inc. | 14.36 Million USD | -62657.504% |
| Molecular Templates, Inc. | 63.09 Million USD | -14190.062% |
| Acrivon Therapeutics, Inc. Common Stock | 66.7 Million USD | -13416.654% |
| Travere Therapeutics, Inc. | 472 Million USD | -1810.107% |
| Monte Rosa Therapeutics, Inc. | 143.31 Million USD | -6191.033% |
| Spruce Biosciences, Inc. | 62.08 Million USD | -14422.314% |
| Celldex Therapeutics, Inc. | 43.41 Million USD | -20666.902% |
| Cogent Biosciences, Inc. | 208.13 Million USD | -4231.784% |
| MacroGenics, Inc. | 217.21 Million USD | -4050.608% |
| RenovoRx, Inc. | 11.39 Million USD | -79013.224% |
| Adicet Bio, Inc. | 152.03 Million USD | -5829.927% |
| Prime Medicine, Inc. | 186.63 Million USD | -4730.578% |
| Aditxt, Inc. | 25.95 Million USD | -34641.723% |
| Adagene Inc. | 41.83 Million USD | -21452.595% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -123232.724% |
| Quantum-Si incorporated | 111.65 Million USD | -7974.354% |
| Maravai LifeSciences Holdings, Inc. | 171.85 Million USD | -5146.286% |
| Acurx Pharmaceuticals, Inc. | 14.57 Million USD | -61745.84% |
| Voyager Therapeutics, Inc. | 35.82 Million USD | -25068.173% |
| SciSparc Ltd. | 9.01 Million USD | -99952.636% |
| Vericel Corporation | 142.04 Million USD | -6247.327% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -104048.007% |
| Minerva Neurosciences, Inc. | 23.08 Million USD | -38948.471% |
| Generation Bio Co. | 144.46 Million USD | -6140.694% |
| Astria Therapeutics, Inc. | 83.03 Million USD | -10758.416% |
| Black Diamond Therapeutics, Inc. | 86.46 Million USD | -10327.646% |
| Arcutis Biotherapeutics, Inc. | 295.72 Million USD | -2948.743% |
| Invivyd, Inc. | 205.75 Million USD | -4281.786% |
| Relay Therapeutics, Inc. | 72.15 Million USD | -12394.274% |
| Quoin Pharmaceuticals, Ltd. | 9.37 Million USD | -96031.995% |
| Spero Therapeutics, Inc. | 75.25 Million USD | -11880.417% |
| Artelo Biosciences, Inc. | 10.28 Million USD | -87542.102% |
| 2seventy bio, Inc. | 289.88 Million USD | -3010.089% |
| ADMA Biologics, Inc. | 66.58 Million USD | -13439.998% |
| Clene Inc. | 41.07 Million USD | -21850.534% |
| Capricor Therapeutics, Inc. | 12.8 Million USD | -70292.124% |
| Boundless Bio, Inc. Common Stock | 54.79 Million USD | -16353.287% |
| GeoVax Labs, Inc. | 6.02 Million USD | -149609.133% |
| Recursion Pharmaceuticals, Inc. | 352.04 Million USD | -2460.941% |
| Citius Pharmaceuticals, Inc. | 36.73 Million USD | -24444.644% |
| Contineum Therapeutics, Inc. Class A Common Stock | 33.72 Million USD | -26630.737% |
| Relmada Therapeutics, Inc. | 103.7 Million USD | -8593.895% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | -27564.988% |
| ALX Oncology Holdings Inc. | 170.27 Million USD | -5194.72% |
| Vir Biotechnology, Inc. | 767.72 Million USD | -1074.353% |
| Evaxion Biotech A/S | 22.27 Million USD | -40383.803% |
| Ocular Therapeutix, Inc. | 135.54 Million USD | -6551.525% |
| Verve Therapeutics, Inc. | 234.88 Million USD | -3738.414% |
| Trevena, Inc. | 38.41 Million USD | -23370.552% |
| Surrozen, Inc. | 18.55 Million USD | -48502.388% |
| Tyra Biosciences, Inc. | 79.94 Million USD | -11177.432% |
| Cingulate Inc. | 22.75 Million USD | -39513.639% |
| Galmed Pharmaceuticals Ltd. | -7.49 Million USD | 120438.267% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -20084.349% |
| Tenax Therapeutics, Inc. | 8.23 Million USD | -109394.87% |
| Terns Pharmaceuticals, Inc. | 102.55 Million USD | -8690.872% |
| ACADIA Pharmaceuticals Inc. | 754.08 Million USD | -1095.587% |
| Connect Biopharma Holdings Limited | 62.07 Million USD | -14424.186% |
| Clearmind Medicine Inc. | 8.74 Million USD | -103039.023% |
| Kronos Bio, Inc. | 128.11 Million USD | -6937.062% |
| Bolt Biotherapeutics, Inc. | 84.07 Million USD | -10623.836% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -307291.378% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -8841.794% |
| Statera Biopharma, Inc. | 28.82 Million USD | -31172.624% |
| ImmunityBio, Inc. | 362.87 Million USD | -2384.552% |
| Korro Bio, Inc. | 84.53 Million USD | -10565.227% |
| Kineta, Inc. | 21.15 Million USD | -42515.537% |
| BioVie Inc. | 31.95 Million USD | -28118.104% |
| Codexis, Inc. | 66.51 Million USD | -13453.84% |
| Celularity Inc. | 215.05 Million USD | -4092.238% |
| Crinetics Pharmaceuticals, Inc. | 226.62 Million USD | -3878.335% |
| Celcuity Inc. | 66.23 Million USD | -13512.71% |
| Virax Biolabs Group Limited | 6.54 Million USD | -137606.679% |
| Cibus, Inc. | 320.3 Million USD | -2714.737% |
| Eledon Pharmaceuticals, Inc. | 43 Million USD | -20866.844% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | -26539.118% |
| IN8bio, Inc. | 30.33 Million USD | -29618.637% |
| Kodiak Sciences Inc. | 277.32 Million USD | -3151.013% |
| Annexon, Inc. | 143.72 Million USD | -6172.999% |
| Adverum Biotechnologies, Inc. | 127.59 Million USD | -6966.128% |
| Assembly Biosciences, Inc. | 22.9 Million USD | -39254.59% |
| Avalo Therapeutics, Inc. | 640 Thousand USD | -1408609.844% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | -1056.477% |
| Eyenovia, Inc. | 25.4 Million USD | -35386.046% |
| Puma Biotechnology, Inc. | 140.31 Million USD | -6325.359% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -161995.343% |
| Xilio Therapeutics, Inc. | 79.13 Million USD | -11293.152% |
| Arcellx, Inc. | 200.19 Million USD | -4403.391% |
| Cardiff Oncology, Inc. | 45.9 Million USD | -19542.142% |
| Enanta Pharmaceuticals, Inc. | 216.41 Million USD | -4066.028% |
| Regulus Therapeutics Inc. | 9.95 Million USD | -90446.781% |
| Moolec Science SA | 52.75 Million USD | -16991.259% |
| Acumen Pharmaceuticals, Inc. | 61.13 Million USD | -14646.546% |
| Geron Corporation | 70.44 Million USD | -12698.999% |
| LAVA Therapeutics N.V. | 46.54 Million USD | -19272.031% |
| Royalty Pharma plc | 862.4 Million USD | -945.42% |
| Atea Pharmaceuticals, Inc. | 94.07 Million USD | -9483.875% |
| Greenwich LifeSciences, Inc. | 9.32 Million USD | -96553.865% |
| TFF Pharmaceuticals, Inc. | 22.62 Million USD | -39742.366% |
| Mersana Therapeutics, Inc. | 207.81 Million USD | -4238.413% |
| Humacyte, Inc. | 23.49 Million USD | -38269.762% |
| Structure Therapeutics Inc. | 102.77 Million USD | -8672.311% |
| 89bio, Inc. | 151.2 Million USD | -5862.635% |
| PMV Pharmaceuticals, Inc. | 80.13 Million USD | -11151.114% |
| Avenue Therapeutics, Inc. | 14.54 Million USD | -61906.486% |
| Genelux Corporation | 24.33 Million USD | -36948.461% |
| Trevi Therapeutics, Inc. | 33.92 Million USD | -26477.08% |
| Lexicon Pharmaceuticals, Inc. | 172.86 Million USD | -5115.361% |
| Notable Labs, Ltd. | 14.77 Million USD | -60940.914% |
| Liquidia Corporation | 87.98 Million USD | -10147.026% |
| Mustang Bio, Inc. | 48.5 Million USD | -18488.778% |
| Immunovant, Inc. | 282.7 Million USD | -3089.054% |
| Quantum-Si incorporated | 111.65 Million USD | -7974.354% |
| Arbutus Biopharma Corporation | 22.54 Million USD | -39891.763% |
| DiaMedica Therapeutics Inc. | 21.26 Million USD | -42293.111% |
| Vera Therapeutics, Inc. | 102.01 Million USD | -8737.924% |
| Acasti Pharma Inc. | 11.3 Million USD | -79678.276% |
| MiNK Therapeutics, Inc. | 22.92 Million USD | -39233.806% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -56321.174% |
| Xenon Pharmaceuticals Inc. | 46.54 Million USD | -19271.198% |
| Elevai Labs, Inc. Common Stock | 1.13 Million USD | -794532.639% |
| NeuroBo Pharmaceuticals, Inc. | 15.88 Million USD | -56652.757% |
| Tempest Therapeutics, Inc. | 29.15 Million USD | -30821.367% |
| Soleno Therapeutics, Inc. | 41.38 Million USD | -21685.577% |
| PepGen Inc. | 84.76 Million USD | -10536.037% |
| Moleculin Biotech, Inc. | 29.63 Million USD | -30326.725% |
| United Therapeutics Corporation | 885.1 Million USD | -918.613% |
| Nuvectis Pharma, Inc. | 22.89 Million USD | -39275.215% |
| Solid Biosciences Inc. | 104.31 Million USD | -8542.806% |
| BriaCell Therapeutics Corp. | 32.72 Million USD | -27449.567% |
| Immuneering Corporation | 58.41 Million USD | -15334.51% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -177018.369% |
| Silo Pharma, Inc. | 3.92 Million USD | -229784.601% |
| Belite Bio, Inc | 31.66 Million USD | -28369.569% |
| XOMA Corporation | 46.46 Million USD | -19304.134% |
| ARS Pharmaceuticals, Inc. | 67.55 Million USD | -13246.77% |
| Bionomics Limited | 17.89 Billion USD | 49.611% |
| Apogee Therapeutics, Inc. | 93 Million USD | -9594.035% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 25368.338% |
| uniQure N.V. | 285.08 Million USD | -3062.464% |
| Cassava Sciences, Inc. | 105.95 Million USD | -8408.87% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -123232.724% |
| Poseida Therapeutics, Inc. | 194.2 Million USD | -4542.337% |
| Forte Biosciences, Inc. | 32.47 Million USD | -27660.394% |
| Anebulo Pharmaceuticals, Inc. | 8.3 Million USD | -108408.952% |
| Enlivex Therapeutics Ltd. | 29.39 Million USD | -30571.009% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -161995.343% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -63346.467% |
| FibroBiologics, Inc. Common Stock | 8.88 Million USD | -101325.841% |
| Altimmune, Inc. | 30.55 Million USD | -29405.639% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | -2008.201% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 25368.338% |
| Compugen Ltd. | 43.97 Million USD | -20403.839% |
| Peak Bio, Inc. | 1249.13 USD | -721761686.203% |
| Zevra Therapeutics, Inc. | 74.12 Million USD | -12063.712% |
| Benitec Biopharma Inc. | 22.38 Million USD | -40181.222% |
| Spyre Therapeutics, Inc. | 243.18 Million USD | -3607.299% |
| NKGen Biotech, Inc. Common Stock | 28.54 Million USD | -31486.529% |
| Zura Bio Limited | 62.63 Million USD | -14293.408% |
| PolyPid Ltd. | 21.04 Million USD | -42740.309% |
| Aileron Therapeutics, Inc. | 16.27 Million USD | -55292.867% |
| NKGen Biotech, Inc. Warrants | 28.54 Million USD | -31486.529% |
| Instil Bio, Inc. | 85.78 Million USD | -10409.696% |
| argenx SE | 1.53 Billion USD | -487.908% |
| Immunome, Inc. | 122.82 Million USD | -7240.615% |
| Compass Therapeutics, Inc. | 48.47 Million USD | -18499.515% |
| Verona Pharma plc | 67.15 Million USD | -13326.018% |
| enGene Holdings Inc. Warrants | 25.88 Million USD | -34729.99% |
| Shattuck Labs, Inc. | 93.61 Million USD | -9530.764% |
| CervoMed Inc. | 14.95 Million USD | -60174.659% |
| LENZ Therapeutics, Inc. | 70.7 Million USD | -12651.571% |
| Plus Therapeutics, Inc. | 8.54 Million USD | -105421.337% |
| Dianthus Therapeutics, Inc. | 51 Million USD | -17577.927% |
| Moolec Science SA | 52.75 Million USD | -16991.259% |
| Enveric Biosciences, Inc. | 16.44 Million USD | -54712.146% |
| Inovio Pharmaceuticals, Inc. | 132.55 Million USD | -6701.504% |
| AnaptysBio, Inc. | 181.56 Million USD | -4865.491% |
| Design Therapeutics, Inc. | 78.19 Million USD | -11430.558% |
| Leap Therapeutics, Inc. | 87.04 Million USD | -10258.042% |
| NeurAxis, Inc. | 8.82 Million USD | -102105.414% |
| Seelos Therapeutics, Inc. | 12.58 Million USD | -71538.8% |
| Lumos Pharma, Inc. | 38.66 Million USD | -23217.582% |
| Achilles Therapeutics plc | 75.25 Million USD | -11880.258% |
| enGene Holdings Inc. Common Stock | 25.88 Million USD | -34729.99% |
| 180 Life Sciences Corp. | 13.47 Million USD | -66794.773% |
| Opiant Pharmaceuticals, Inc. | 26.5 Million USD | -33918.537% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -307291.378% |
| Nutriband Inc. | 5.73 Million USD | -157132.198% |
| ORIC Pharmaceuticals, Inc. | 110.78 Million USD | -8038.421% |
| CG Oncology, Inc. Common stock | 55.65 Million USD | -16099.923% |
| Fractyl Health, Inc. Common Stock | 50.87 Million USD | -17619.969% |
| Rani Therapeutics Holdings, Inc. | 66.09 Million USD | -13539.757% |
| MoonLake Immunotherapeutics | 54.12 Million USD | -16557.848% |
| Palisade Bio, Inc. | 13.32 Million USD | -67585.758% |
| Tourmaline Bio, Inc. | 45.4 Million USD | -19754.529% |
| Beam Therapeutics Inc. | 554.19 Million USD | -1526.821% |
| Neurogene Inc. | 55.58 Million USD | -16120.325% |
| Mirum Pharmaceuticals, Inc. | 248.48 Million USD | -3528.226% |
| AEON Biopharma, Inc. | 48.42 Million USD | -18516.414% |
| CARGO Therapeutics, Inc. Common Stock | 96.71 Million USD | -9222.452% |
| Sesen Bio, Inc. | 78.38 Million USD | -11402.46% |
| Enliven Therapeutics, Inc. | 83.52 Million USD | -10693.548% |
| Kiora Pharmaceuticals, Inc. | 12.58 Million USD | -71528.009% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | -1899.087% |
| Taysha Gene Therapies, Inc. | 87.89 Million USD | -10157.985% |
| Athira Pharma, Inc. | 125.46 Million USD | -7085.806% |
| Vaccinex, Inc. | 23.45 Million USD | -38338.469% |
| HCW Biologics Inc. | 21.02 Million USD | -42775.922% |
| XOMA Corporation | 46.46 Million USD | -19304.134% |
| Nektar Therapeutics | 190.9 Million USD | -4622.683% |
| Arvinas, Inc. | 480 Million USD | -1778.28% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -396375.899% |
| Merus N.V. | 200.49 Million USD | -4396.764% |
| Omega Therapeutics, Inc. | 103.35 Million USD | -8623.084% |
| Quince Therapeutics, Inc. | 34.62 Million USD | -25942.008% |
| Rezolute, Inc. | 70.38 Million USD | -12708.818% |
| Clene Inc. | 41.07 Million USD | -21850.534% |
| Indaptus Therapeutics, Inc. | 16.37 Million USD | -54946.294% |
| BeyondSpring Inc. | 24.86 Million USD | -36158.769% |
| Synlogic, Inc. | 58.53 Million USD | -15303.101% |
| Allarity Therapeutics, Inc. | 17.89 Million USD | -50289.8% |
| Phio Pharmaceuticals Corp. | 4.49 Million USD | -200606.656% |
| Peak Bio, Inc. | 1249.13 USD | -721761686.203% |
| Werewolf Therapeutics, Inc. | 60.44 Million USD | -14815.367% |
| Krystal Biotech, Inc. | 160.42 Million USD | -5519.876% |
| Karyopharm Therapeutics Inc. | 270.63 Million USD | -3231.379% |
| SpringWorks Therapeutics, Inc. | 348.03 Million USD | -2490.448% |
| Lipella Pharmaceuticals Inc. | 2.15 Million USD | -417927.582% |
| MannKind Corporation | 125.59 Million USD | -7078.311% |
| Ikena Oncology, Inc. | 84.57 Million USD | -10559.805% |
| Cyclerion Therapeutics, Inc. | 9.64 Million USD | -93356.442% |
| Gyre Therapeutics, Inc. | 89.6 Million USD | -9962.101% |
| Gossamer Bio, Inc. | 183.75 Million USD | -4806.286% |
| CohBar, Inc. | 12.38 Million USD | -72676.29% |
| Cognition Therapeutics, Inc. | 50.72 Million USD | -17674.117% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -32587.053% |
| Legend Biotech Corporation | 583.14 Million USD | -1446.055% |
| Mural Oncology plc | 192.07 Million USD | -4593.964% |
| Biora Therapeutics, Inc. | 67.14 Million USD | -13326.874% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | -55741.385% |
| Disc Medicine, Inc. | 91.12 Million USD | -9793.819% |
| Champions Oncology, Inc. | 28.11 Million USD | -31973.081% |
| REGENXBIO Inc. | 321.15 Million USD | -2707.27% |
| Ensysce Biosciences, Inc. | 5.36 Million USD | -168065.445% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -16069.996% |
| Cellectar Biosciences, Inc. | 38.96 Million USD | -23040.642% |
| Edgewise Therapeutics, Inc. | 114.35 Million USD | -7783.858% |
| Vaxart, Inc. | 90.72 Million USD | -9837.331% |
| PharmaCyte Biotech, Inc. | 8.52 Million USD | -105718.48% |
| Aldeyra Therapeutics, Inc. | 42.79 Million USD | -20967.733% |
| Cellectis S.A. | 97.32 Million USD | -9164.019% |
| Longeveron Inc. | 21.25 Million USD | -42327.026% |
| Repare Therapeutics Inc. | 167.35 Million USD | -5287.132% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | -562.524% |
| Inozyme Pharma, Inc. | 75.64 Million USD | -11818.492% |
| Revolution Medicines, Inc. | 498.76 Million USD | -1707.613% |
| Nymox Pharmaceutical Corporation | 6.65 Million USD | -135434.321% |
| Third Harmonic Bio, Inc. | 43.95 Million USD | -20411.769% |
| ArriVent BioPharma, Inc. Common Stock | 74.59 Million USD | -11987.067% |
| AN2 Therapeutics, Inc. | 69.63 Million USD | -12847.143% |
| Anixa Biosciences, Inc. | 11.06 Million USD | -81416.664% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | -88.811% |
| Denali Therapeutics Inc. | 527.23 Million USD | -1610.021% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -104048.007% |
| Veru Inc. | 101.34 Million USD | -8795.815% |
| Corvus Pharmaceuticals, Inc. | 23.4 Million USD | -38417.294% |
| Cingulate Inc. | 22.75 Million USD | -39513.639% |
| Passage Bio, Inc. | 108.38 Million USD | -8217.95% |
| Context Therapeutics Inc. | 25.07 Million USD | -35858.525% |
| Exicure, Inc. | 14.07 Million USD | -63950.462% |
| Day One Biopharmaceuticals, Inc. | 206.06 Million USD | -4275.215% |
| Oramed Pharmaceuticals Inc. | 43.3 Million USD | -20721.097% |
| Scinai Immunotherapeutics Ltd. | 9.17 Million USD | -98139.709% |
| Rhythm Pharmaceuticals, Inc. | 252.48 Million USD | -3470.832% |
| Nuvalent, Inc. | 149.49 Million USD | -5930.92% |
| ABVC BioPharma, Inc. | 8.06 Million USD | -111662.149% |
| Carisma Therapeutics, Inc. | 103.65 Million USD | -8598.257% |
| Unicycive Therapeutics, Inc. | 21.44 Million USD | -41933.395% |
| OmniAb, Inc. | 83.89 Million USD | -10646.46% |
| Anew Medical, Inc. | 1.3 Million USD | -692970.329% |
| Fennec Pharmaceuticals Inc. | 32.76 Million USD | -27417.223% |
| Lipocine Inc. | 15.08 Million USD | -59685.543% |
| Lexeo Therapeutics, Inc. Common Stock | 68.51 Million USD | -13059.171% |
| Nautilus Biotechnology, Inc. | 76.15 Million USD | -11739.141% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -22263.629% |
| G1 Therapeutics, Inc. | 114.84 Million USD | -7750.494% |
| Bellerophon Therapeutics, Inc. | 22.38 Million USD | -40177.622% |
| Sage Therapeutics, Inc. | 664.14 Million USD | -1257.496% |
| Ocugen, Inc. | 71.56 Million USD | -12497.626% |
| Mind Medicine (MindMed) Inc. | 93.86 Million USD | -9504.908% |
| Q32 Bio Inc. | 92.68 Million USD | -9627.819% |
| Brainstorm Cell Therapeutics Inc. | 21.17 Million USD | -42479.31% |
| Alumis Inc. Common Stock | 158.17 Million USD | -5599.889% |
| Equillium, Inc. | 50.6 Million USD | -17715.561% |
| Kyverna Therapeutics, Inc. | 62.4 Million USD | -14346.917% |
| Coya Therapeutics, Inc. | 13.9 Million USD | -64735.55% |
| CNS Pharmaceuticals, Inc. | 18.86 Million USD | -47690.572% |
| Galera Therapeutics, Inc. | 46.95 Million USD | -19102.451% |
| Evelo Biosciences, Inc. | 108.46 Million USD | -8212.045% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | -72650.275% |
| Dominari Holdings Inc. | 23.83 Million USD | -37725.647% |
| Edesa Biotech, Inc. | 9.22 Million USD | -97655.389% |
| vTv Therapeutics Inc. | 11.9 Million USD | -75618.006% |
| Bio-Techne Corporation | 563.03 Million USD | -1501.264% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | -2105.384% |
| Harmony Biosciences Holdings, Inc. | 268.75 Million USD | -3254.62% |
| Prelude Therapeutics Incorporated | 132.27 Million USD | -6715.805% |
| Candel Therapeutics, Inc. | 14.41 Million USD | -62461.536% |
| iTeos Therapeutics, Inc. | 163.69 Million USD | -5407.614% |
| Nkarta, Inc. | 131.65 Million USD | -6748.267% |
| BioCardia, Inc. | 12.12 Million USD | -74281.181% |
| Iterum Therapeutics plc | 47.46 Million USD | -18893.307% |